Remdesivir reduced upper respiratory tract SARS-CoV-2 viral RNA concentration in COVID-19 patients who developed pneumonitis - 29/11/22
Doi : 10.1016/j.jinf.2022.08.031
Christopher KC Lai a, 1, Grace CY Lui b, c, 1, Yuchen Wei d, 1, Ka Chun Chong d, Zigui Chen a, Lowell Ling e, Rita WY Ng a, Siaw SS Boon a, Wendy CS Ho a, Apple CM Yeung a, David SC Hui b, c, Paul KS Chan a, c, ⁎ 
a Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, 1/F, Clinical Sciences Building, Prince of Wales Hospital, 30-32 Ngan Shing Street, N.T., Shatin, China Hong Kong Special Administrative Region
b Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, China Hong Kong Special Administrative Region
c Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, China Hong Kong Special Administrative Region
d School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, China Hong Kong Special Administrative Region
e Department of Anaesthesia and Intensive Care, Faculty of Medicine of Medicine, The Chinese University of Hong Kong, China Hong Kong Special Administrative Region
⁎Corresponding author at: Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, 1/F, Clinical Sciences Building, Prince of Wales Hospital, 30-32 Ngan Shing Street, N.T., Shatin, China Hong Kong Special Administrative Region.Department of MicrobiologyFaculty of MedicineThe Chinese University of Hong Kong1/F, Clinical Sciences Building, Prince of Wales Hospital, 30-32 Ngan Shing Street, N.T.ShatinChina Hong Kong Special Administrative Region
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | COVID-19 patients with pneumonitis benefit from antiviral treatment. |
• | Early remdesivir treatment accelerates the decline in SARS-CoV-2 respiratory concentration. |
• | The significant viral load decline was observed from day 8 onwards after admission. |
Keywords : COVID-19, SARS-CoV-2, Remdesivir, Anti-viral, Treatment, Viral load, Viral kinetics, Clinical, Virological
Plan
© 2022
Publié par Elsevier Masson SAS.
Vol 85 - N° 6
P. 702-769 - décembre 2022 Retour au numéro
Article précédent
- Post-vaccination SARS-CoV-2 antibody kinetics and protection duration against Omicron in elderly population
- Chloé Dimeglio, Pauline Trémeaux, Fabrice Herin, Isabelle Da-Silva, Marion Porcheron, Guillaume Martin-Blondel, Caroline Gernigon, Sabine Chapuy-Regaud, Hélène Villars, Jacques Izopet
- Antibody response and safety of COVID-19 vaccine in peritoneal dialysis patients
- Qian Zheng, Mingwei Wang, Yongran Cheng, Jiming Liu, Zhanhui Feng, Lan Ye
Bienvenue sur EM-consulte, la référence des professionnels de santé.